Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Frequent RBM10 Comutation and a Mutually Exclusive Relationship With Other TP53 Pathway Aberrations in Early-Stage Non-Small-Cell Lung Cancer with EGFR Mutation.

Clinical lung cancer - 1 May 2026

Suda Kenichi, Sakai Kazuko, Ito Masaoki, Oiki Hana, Fukuda Shota, Ohara Shuta, Hamada Akira, Chiba Masato, Shimoji Masaki, Nishio Kazuto, Tsutani Yasuhiro

Abstract excerpt

BACKGROUND: RNA-binding motif 10 (RBM10) mutation in non-small-cell lung cancer (NSCLC) is associated with decreased sensitivity to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in vitro and in patients who received osimertinib as neoadjuvant treatment or palliative systemic therapy. The incidence of this mutation in early-stage NSCLC and the relationship with other mutations are unknown....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins c-mdm2

Share to RNA-Binding Proteins

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 41934032
DOI: 10.1016/j.cllc.2026.03.002

Genes

RBM10
EGFR
KRAS
MDM2
TP53

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Frequent RBM10 Comutation and a Mutually Exclusive Relationship With Other TP53 Pathway Aberrations in Early-Stage Non-Small-Cell Lung Cancer with EGFR Mutation.PMID 41934032Read ↗

RBM10 Mutation as a Potential Negative Prognostic/Predictive Biomarker to Therapy in Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy.Semantic proximity Read ↗

Investigation of RBM10 mutation and its associations with clinical and molecular characteristics in EGFR-mutant and EGFR-wildtype lung adenocarcinomaSemantic proximity Read ↗

Whole Exome Sequencing Study Identifies Distinct Characteristics of Transformed Small Cell Lung Cancer With EGFR Mutation Compared to De Novo Small Cell and Primary Non‐Small Cell Lung CancersSemantic proximity Read ↗

Prevalence of Genomic Alterations in EGFR, KRAS, NRAS, and BRAF Among Early-Stage Nonsquamous Non-Small Cell Lung Cancer in Brazil.Semantic proximity Read ↗

The role of RBM10 mutations in the development, treatment, and prognosis of lung adenocarcinoma.Semantic proximity Read ↗

Coexistence of a primary ALK-positive and MET14 exon skipping mutation double-fusion in one patient with NSCLC and response to crizotinib: A case report and literature review.Semantic proximity Read ↗

RBM10 Loss Promotes EGFR-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition.Semantic proximity Read ↗

Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancerSemantic proximity Read ↗

RBM10, a New Regulator of p53Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.